EXHIBIT 10.5
Transition Agreement
This Transition Agreement (the “Agreement”) is made as of October 3, 2023 (the “Notice Date”), by and between SQZ Biotechnologies Company (the “Company”) and Marshelle Smith Warren (the “Executive”) (collectively referred to as the “parties” or individually referred to as a “party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below).
WHEREAS, the Company is in the process of pursuing various strategic alternatives (the “Transition”); and
WHEREAS, in light of the anticipated Transition and the Company’s current business needs, the parties desire to amend certain terms of Executive’s employment, including Executive’s Employment Agreement with the Company, dated as of May 25, 2022 (the “Employment Agreement”), as provided in this Agreement.
NOW, THEREFORE, in exchange for the good and valuable consideration set forth herein, the sufficiency of which is specifically acknowledged, the Company and Executive hereby agree as follows:
|US-DOCS\145318647.2||
2
|US-DOCS\145318647.2||
3
|US-DOCS\145318647.2||
[Signature Page Follows]
4
|US-DOCS\145318647.2||
IN WITNESS WHEREOF, the parties have executed this Agreement on the respective dates set forth below.
|
|
Dated: |
|
|
|
| SQZ Biotechnologies Company
|
Dated: | By: |
[Signature Page to Transition Agreement]